Achilladelis, B., & Antonakis, N. (2001). The dynamics of technological innovation: The case of the pharmaceutical industry. Research Policy, 30(4), 535–588. https://doi.org/10.1016/S0048-7333(00)00093-7.
Article
Google Scholar
Ahuja, G. (2000). Collaboration networks, structural holes, and innovation: A longitudinal study. Administrative Science Quarterly. https://doi.org/10.2307/2667105.
Article
Google Scholar
Anand, G., Gray, J., & Siemsen, E. (2012). Decay, shock, and renewal: Operational routines and process entropy in the pharmaceutical industry. Organization Science, 23(6), 1700–1716. https://doi.org/10.1287/orsc.1110.0709.
Article
Google Scholar
Arundel, A., & Kabla, I. (1998). What percentage of innovations are patented? empirical estimates for European firms. Research Policy, 27(2), 127–141. https://doi.org/10.1016/S0048-7333(98)00033-X.
Article
Google Scholar
Athreye, S., Kale, D., & Ramani, S. V. (2009). Experimentation with strategy and the evolution of dynamic capability in the Indian pharmaceutical sector. Industrial and Corporate Change, 18(4), 729–759. https://doi.org/10.1093/icc/dtp024.
Article
Google Scholar
Baregheh, A., Rowley, J., & Sambrook, S. (2009). Towards a multidisciplinary definition of innovation. Management Decision. https://doi.org/10.1108/00251740910984578.
Article
Google Scholar
Barney, J. (1991). Firm resources and sustained competitive advantage. Journal of Management, 17(1), 99–120. https://doi.org/10.1177/014920639101700108.
Article
Google Scholar
Ben-Menahem, S. M., von Krogh, G., Erden, Z., & Schneider, A. (2016). Coordinating knowledge creation in multidisciplinary Teams: Evidence from early-stage drug discovery. Academy of Management Journal, 59(4), 1308–1338. https://doi.org/10.5465/amj.2013.1214.
Article
Google Scholar
Bianchi, M., Cavaliere, A., Chiaroni, D., Frattini, F., & Chiesa, V. (2011). Organisational modes for Open Innovation in the bio-pharmaceutical industry: An exploratory analysis. Technovation, 31(1), 22–33. https://doi.org/10.1016/j.technovation.2010.03.002.
Article
Google Scholar
Bierly, P., & Chakrabarti, A. (1996). Generic knowledge strategies in the U.S. pharmaceutical industry. Strategic Management Journal, 17(S2), 123–135. https://doi.org/10.1002/smj.4250171111.
Article
Google Scholar
Bird, S., Klein, E., & Loper, E. (2009). Natural Language Processing with Python. Newton: O’Reilly Media Inc. https://doi.org/10.1097/00004770-200204000-00018.
Book
MATH
Google Scholar
Blau, G. E., Pekny, J. F., Varma, V. A., & Bunch, P. R. (2004). Managing a portfolio of interdependent new product candidates in the pharmaceutical industry. Journal of Product Innovation Management. https://doi.org/10.1111/j.0737-6782.2004.00075.x.
Article
Google Scholar
Bogart, S. (2018). SankeyMATIC: A Sankey diagram builder for everyone. https://sankeymatic.com. Accessed 15 Oct 2018.
Bogner, W. C., Thomas, H., & Mcgee, J. (1996). A longitudinal study of the competitive positions and entry paths of European firms in the U.S. pharmaceutical market. Strategic Management Journal, 17(2), 85–107. https://doi.org/10.1002/(SICI)1097-0266(199602)17:2<85:AID-SMJ785>3.0.CO;2-D.
Article
Google Scholar
Bresman, H. (2010). External learning activities and team performance: A multimethod field study. Organization Science, 21(1), 81–96.
Article
Google Scholar
Bresman, H. (2013). Changing routines: A process model of vicarious group learning in pharmaceutical R & D. Academy of Management Journal, 56(1), 35–61. https://doi.org/10.5465/amj.2010.0725.
Article
Google Scholar
Bresman, H., & Zellmer-Bruhn, M. (2013). The structural context of team learning: Effects of organizational and team structure on internal and external learning. Organization Science, 24(4), 1120–1139. https://doi.org/10.1287/orsc.1120.0783.
Article
Google Scholar
Burt, R. S. (1992). Structural Holes: The social Structure of Competition. Cambridge, Massachussetts: Harvard University Press. https://doi.org/10.1177/0265407512465997.
Book
Google Scholar
Carlsson, B., Jacobsson, S., Holmén, M., & Rickne, A. (2002). Innovation systems: Analytical and methodological issues. Research Policy, 31(2), 233–245. https://doi.org/10.1016/S0048-7333(01)00138-X.
Article
Google Scholar
Casper, S., & Matraves, C. (2003). Institutional frameworks and innovation in the German and UK pharmaceutical industry. Research Policy, 32(10), 1865–1879. https://doi.org/10.1016/S0048-7333(03)00082-9.
Article
Google Scholar
Chesbrough, H., & Crowther, A. K. A. (2006). Beyond high tech : Early adopters of open innovation in other industries. R&d Management, 36, 229–236.
Article
Google Scholar
Chesbrough, H. W. (2003). Open Innovation: The new imperative for creating and profiting from technology. Boston: Harvard Business School Press. https://doi.org/10.1111/j.1467-8691.2008.00502.x.
Book
Google Scholar
Cohen, F. J. (2005). Opinion: Macro trends in pharmaceutical innovation. Nature Reviews Drug Discovery. https://doi.org/10.1038/nrd1610.
Article
Google Scholar
Cohen, W. M., & Levinthal, D. A. (1990). Absorptive capacity: A new perspective on learning and innovation. Administrative Science Quarterly, 35(1), 128. https://doi.org/10.2307/2393553.
Article
Google Scholar
Cohen, W., Nelson, R., & Walsh, J. (2000). Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not). Cambridge, MA. https://doi.org/10.3386/w7552
Coleman, J. S. (1988). Social capital in the creation of human-capital. American Journal of Sociology, 94, S95–S120. https://doi.org/10.1086/228943.
Article
Google Scholar
Cool, K., & Dierickx, I. (1993). Rivalry, strategic groups and firm profitability. Strategic Management Journal, 14(1), 47–59. https://doi.org/10.1002/smj.4250140106.
Article
Google Scholar
Cool, K. O., & Schendel, D. (1987). Strategic group formation and performance: The case of the U.S. pharmaceutical industry 1963–1982. Management Science. https://doi.org/10.1287/mnsc.33.9.1102.
Article
Google Scholar
Cowlrick, I., Hedner, T., Wolf, R., Olausson, M., & Klofsten, M. (2011). Decision-making in the pharmaceutical industry: Analysis of entrepreneurial risk and attitude using uncertain information. R and D Management, 41(4), 321–336. https://doi.org/10.1111/j.1467-9310.2011.00649.x.
Article
Google Scholar
Crossan, M. M., & Apaydin, M. (2010). A multi-dimensional framework of organizational innovation: A systematic review of the literature. Journal of Management Studies, 47(September), 1154–1191. https://doi.org/10.1111/j.1467-6486.2009.00880.x.
Article
Google Scholar
D’Este, P., & Perkmann, M. (2011). Why do academics engage with industry? The entrepreneurial university and individual motivations. Journal of Technology Transfer, 36(3), 316–339. https://doi.org/10.1007/s10961-010-9153-z.
Article
Google Scholar
Demirel, P., & Mazzucato, M. (2012). Innovation and firm growth: Is R&D worth It? Industry & Innovation, 19(1), 45–62. https://doi.org/10.1080/13662716.2012.649057.
Article
Google Scholar
Dickson, M., & Gagnon, J. (2004). Key factors in the rising cost of new drug discovery and development. Nature Reviews Drug Discovery, 3, 417–429.
Article
Google Scholar
Dierickx, I., & Cool, K. (1989). Asset stock accumulation and the sustainability of competitive advantage: Reply. Management Science. https://doi.org/10.1287/mnsc.35.12.1514.
Article
Google Scholar
Diestre, L., & Rajagopalan, N. (2012). Are all ‘sharks’ dangerous? new biotechnology ventures and partner selection in R&D alliances. Strategic Management Journal, 33(10), 1115–1134. https://doi.org/10.1002/smj.1978.
Article
Google Scholar
DiMasi, J. A., Grabowski, H. G., & Hansen, R. W. (2016). Innovation in the pharmaceutical industry: New estimates of R&D costs. Journal of Health Economics, 47, 20–33. https://doi.org/10.1016/j.jhealeco.2016.01.012.
Article
Google Scholar
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003). The price of innovation: New estimates of drug development costs. Journal of Health Economics. https://doi.org/10.1016/S0167-6296(02)00126-1.
Article
Google Scholar
DiMasi, J. A., Hansen, R. W., Grabowski, H. G., & Lasagna, L. (1991). Cost of innovation in the pharmaceutical industry. Journal of Health Economics, 10(2), 107–142. https://doi.org/10.1016/0167-6296(91)90001-4.
Article
Google Scholar
Dong, J. Q., & Yang, C. (2016). Being central is a double-edged sword: Knowledge network centrality and new product development in U.S. pharmaceutical industry. Technological Forecasting and Social Change, 113, 379–385. https://doi.org/10.1016/j.techfore.2016.07.011.
Article
Google Scholar
Eisenhardt, K. M. (1989). Building theories from case study research. Academy of Management Review. https://doi.org/10.5465/amr.1989.4308385.
Article
Google Scholar
Festel, G., De Cleyn, S. H., Boutellier, R., & Braet, J. (2011). OPTIMIZING THE R&D PROCESS USING SPIN-OUTS : Case studies from the pharmaceutical industry. Research Technology Managemnt. https://doi.org/10.5437/08953608X540132.
Article
Google Scholar
Festel, G. W. (2013). The nature of outsourced preclinical research—the example of chemical synthesis. Expert Opinion on Drug Discovery. https://doi.org/10.1517/17460441.2013.806909.
Article
Google Scholar
Gambardella, A. (1980s). Competitive advantages from in-house scientific research: The US pharmaceutical industry in the 1980s. Research Policy, 21(5), 391–407. https://doi.org/10.1016/0048-7333(92)90001-K.
Article
Google Scholar
Gilsing, V., & Nooteboom, B. (2006). Exploration and exploitation in innovation systems: The case of pharmaceutical biotechnology. Research Policy, 35(1), 1–23. https://doi.org/10.1016/j.respol.2005.06.007.
Article
Google Scholar
Gilsing, V., Nooteboom, B., Vanhaverbeke, W., Duysters, G., & Van Den Oord, A. (2008). Network embeddedness and the exploration of novel technologies : Technological distance, betweenness centrality and density. Research policy, 37, 1717–1731. https://doi.org/10.1016/j.respol.2008.08.010.
Article
Google Scholar
Glänzel, W., & Thijs, B. (2017). Using hybrid methods and ‘core documents’ for the representation of clusters and topics: The astronomy dataset. Scientometrics. https://doi.org/10.1007/s11192-017-2301-6.
Article
Google Scholar
Grabowski, H. (2002). Patents, innovation and access to new pharmaceuticals. Journal of International Economic Law, 5(4), 849–860.
Article
Google Scholar
Grabowski, H., & Vernon, J. (1990). A new look at the returns and risks to pharmaceutical research- and-development. Management Science, 36, 804–821.
Article
Google Scholar
Grigoriou, K., & Rothaermel, F. T. (2017). Organizing for knowledge generation: Internal knowledge networks and the contingent effect of external knowledge sourcing. Strategic Management Journal. https://doi.org/10.1002/smj.2489.
Article
Google Scholar
Guennif, S., & Ramani, S. V. (2012). Explaining divergence in catching-up in pharma between India and Brazil using the NSI framework. Research Policy, 41(2), 430–441. https://doi.org/10.1016/j.respol.2011.09.005.
Article
Google Scholar
Gulati, R. (1998). Alliances and networks. Strategic Management Journal, 19(4), 293–317. https://doi.org/10.1002/(SICI)1097-0266(199804)19:4<293:AID-SMJ982>3.0.CO;2-M.
Article
Google Scholar
Guo, Y., Hu, Y., Zheng, M., & Wang, Y. (2013). Patent indicators: A window to pharmaceutical market success. Expert Opinion on Therapeutic Patents, 23(7), 765–771.
Article
Google Scholar
Hagedoorn, J. (1993). Understanding the rationale of strategic technology partnering: Interorganizational modes of cooperation and sectoral differences. Strategic management journal, 14(5), 371–385. https://doi.org/10.1002/smj.4250140505.
Article
Google Scholar
Hall, B. H., Jaffe, A., & Trajtenberg, M. (2005). Market value and patent citations. RAND Journal of Economics, 36(1), 16–38.
Google Scholar
Harhoff, D., Scherer, F. M., & Vopel, K. (2003). Citations, family size, opposition and the value of patent rights. Research Policy, 32(8), 1343–1363. https://doi.org/10.1016/S0048-7333(02)00124-5.
Article
Google Scholar
Hay, M., Thomas, D. W., Craighead, J. L., Economides, C., & Rosenthal, J. (2014). Clinical development success rates for investigational drugs. Nature Biotechnology. https://doi.org/10.1038/nbt.2786.
Article
Google Scholar
Heemstra, H. E., de Vrueh, R. L. A., van Weely, S., Büller, H. A., & Leufkens, H. G. M. (2008). Orphan drug development across Europe: Bottlenecks and opportunities. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2008.05.001.
Article
Google Scholar
Henderson, R., & Cockburn, I. (1994). Measuring competence? exploring firm effects in pharmaceutical research. Strategic Management Journal, 15(S1), 63–84. https://doi.org/10.1002/smj.4250150906.
Article
Google Scholar
Hitt, M. A., Beamish, P. W., Jackson, S. E., & Mathieu, J. E. (2007). Building theoretical and empirical bridges across levels: Multilevel research in management. Academy of Management Journal. https://doi.org/10.5465/AMJ.2007.28166219.
Article
Google Scholar
Hoang, H., & Rothaermel, F. T. (2005). The effect of general and partner-specific alliance experience on joint R&D project Performance. Academy of Management Journal, 48(2), 332–345. https://doi.org/10.5465/amj.2005.16928417.
Article
Google Scholar
Hopkins, M. M., Martin, P. A., Nightingale, P., Kraft, A., & Mahdi, S. (2007). The myth of the biotech revolution: An assessment of technological, clinical and organisational change. Research Policy, 36(4), 566–589. https://doi.org/10.1016/j.respol.2007.02.013.
Article
Google Scholar
Hughes, B., & Wareham, J. (2010). Knowledge arbitrage in global pharma: A synthetic view of absorptive capacity and open innovation. R&D Management, 40(3), 324–343. https://doi.org/10.1111/j.1467-9310.2010.00594.x.
Article
Google Scholar
Hunter, J., & Stephens, S. (2010). Is open innovation the way forward for big pharma? Nature Reviews Drug Discovery, 9(2), 87–88. https://doi.org/10.1038/nrd3099.
Article
Google Scholar
Jacob, W. F., & Kwak, Y. H. (2003). In search of innovative techniques to evaluate pharmaceutical R&D projects. Technovation, 23(4), 291–296. https://doi.org/10.1016/S0166-4972(01)00116-X.
Article
Google Scholar
Kale, D., & Little, S. (2007). From imitation to innovation: The evolution of R&fD capabilities and learning processes in the Indian pharmaceutical industry. Technology Analysis & Strategic Management, 19(5), 589–609. https://doi.org/10.1080/09537320701521317.
Article
Google Scholar
Kapoor, R., & Klueter, T. (2015). Decoding the adaptability-rigidity puzzle: Evidence from pharmaceutical incumbents’ pursuit of gene therapy and monoclonal antibodies. Academy of Management Journal, 58(4), 1180–1207. https://doi.org/10.5465/amj.2013.0430.
Article
Google Scholar
Kneller, R. (2010). The importance of new companies for drug discovery: Origins of a decade of new drugs. Nature Reviews Drug Discovery, 9(11), 867–882. https://doi.org/10.1038/nrd3251.
Article
Google Scholar
Kuemmerle, W. (1999). Foreign direct investment in industrial research in the pharmaceutical and electronics industries—results from a survey of multinational firms. Research Policy, 28(2–3), 179–193. https://doi.org/10.1016/S0048-7333(98)00110-3.
Article
Google Scholar
Lane, P. J., & Lubatkin, M. (1998). Relative absorptive capacity and interorganizational learning. Strategic Management Journal, 19(5), 461–477. https://doi.org/10.1002/(SICI)1097-0266(199805)19:5<461:AID-SMJ953>3.3.CO;2-C.
Article
Google Scholar
Laursen, K., & Salter, A. (2006). Open for innovation: The role of openness in explaining innovation performance among U.K. manufacturing firms. Strategic Management Journal, 27(2), 131–150. https://doi.org/10.1002/smj.507.
Article
Google Scholar
Lemus, J., & Marshall, G. (2018). When the clock starts ticking: Measuring strategic responses to TRIPS’s patent term change. Research Policy. https://doi.org/10.1016/j.respol.2018.02.008.
Article
Google Scholar
Liu, C. C., Srivastava, S. B., & Stuart, T. E. (2015). An intraorganizational ecology of individual attainment. Organization Science. https://doi.org/10.1287/orsc.2015.1020.
Article
Google Scholar
Liu, Q., Gupta, S., Venkataraman, S., & Liu, H. (2016). An empirical model of drug detailing: Dynamic competition and policy implications. Management Science, 62(8), 2321–2340. https://doi.org/10.1287/mnsc.2015.2239.
Article
Google Scholar
Lundvall, B.-Å. (1993). National systems of innovation: Towards a theory of innovation and interactive learning. Prometheus. https://doi.org/10.1080/08109029308629360.
Article
Google Scholar
Malerba, F., & Orsenigo, L. (2015). The evolution of the pharmaceutical industry. Business History, 57(5), 664–687. https://doi.org/10.1080/00076791.2014.975119.
Article
Google Scholar
Mansfield, E. (1986). Patents and innovation: An empirical study. Management Science, 32(2), 173–181. https://doi.org/10.1287/mnsc.32.2.173.
Article
Google Scholar
March, J. G. (1991). Exploration and exploitation in organizational learning. Organization Science, 2(1), 71–87. https://doi.org/10.1287/orsc.2.1.71.
Article
Google Scholar
Mason, R., & Drakeman, D. L. (2014). Comment on “fishing for sharks: Partner selection in biopharmaceutical R&D alliances” by diestre and rajagopalan. Strategic Management Journal, 35(10), 1564–1565. https://doi.org/10.1002/smj.2177.
Article
Google Scholar
McGee, J., & Thomas, H. (1986). Strategic groups: Theory, research and taxonomy. Strategic Management Journal. https://doi.org/10.1002/smj.4250070204.
Article
Google Scholar
McMillan, G. S., Narin, F., & Deeds, D. L. (2000). An analysis of the critical role of public science in innovation: The case of biotechnology. Research Policy. https://doi.org/10.1016/S0048-7333(99)00030-X.
Article
Google Scholar
Mittra, J., Tait, J., & Wield, D. (2011). From maturity to value-added innovation: Lessons from the pharmaceutical and agro-biotechnology industries. Trends in Biotechnology. https://doi.org/10.1016/j.tibtech.2010.11.004.
Article
Google Scholar
Mizik, N., & Jacobson, R. (2004). Are physicians “easy marks”? quantifying the effects of detailing and sampling on new prescriptions. Management Science, 50(12), 1704–1715. https://doi.org/10.1287/mnsc.1040.0281.
Article
Google Scholar
Moors, E. H. M., Cohen, A. F., & Schellekens, H. (2014). Towards a sustainable system of drug development. Drug Discovery Today, 19(11), 1711–1720. https://doi.org/10.1016/j.drudis.2014.03.004.
Article
Google Scholar
Moran, P. (2005). Structural vs relational embeddedness: Social capital and managerial performance. Strategic Management Journal, 26(12), 1129–1151. https://doi.org/10.1002/smj.486.
Article
Google Scholar
Natsukawa, T., Gemba, K., & Ishida, S. (2013). The timing of interorganisational collaborations in an emerging biopharmaceutical field: Evidence from Japan in comparison to the remaining RNAi field. Technology Analysis and Strategic Management, 25(5), 583–597. https://doi.org/10.1080/09537325.2013.785509.
Article
Google Scholar
Nelson, R. R. (1993). National Innovation Systems: A Comparative Analysis. Oxford: Oxford University Press.
Google Scholar
Nelson, R. R., & Winter, S. G. (1982). An evolutionary theory of economic change. Cambridge MA Belknap. https://doi.org/10.2307/2232409.
Article
Google Scholar
Orsenigo, L., Pammolli, F., & Riccaboni, M. (2001). Technological change and network dynamics: Lessons from the pharmaceutical industry. Research Policy, 30(3), 485–508. https://doi.org/10.1016/S0048-7333(00)00094-9.
Article
Google Scholar
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011). The productivity crisis in pharmaceutical R&D. Nature Reviews Drug Discovery, 10(6), 428–438. https://doi.org/10.1038/nrd3405.
Article
Google Scholar
Paruchuri, S. (2010). Intraorganizational networks, interorganizational networks, and the impact of central inventors: A longitudinal study of pharmaceutical firms. Organization Science, 21(1), 63–80. https://doi.org/10.1287/orsc.1080.0414.
Article
Google Scholar
Patel, M. N., Halling-Brown, M. D., Tym, J. E., Workman, P., & Al-Lazikani, B. (2013). Objective assessment of cancer genes for drug discovery. Nature Reviews Drug Discovery, 12(1), 35–50.
Article
Google Scholar
Patterson, W., & Ambrosini, V. (2015). Configuring absorptive capacity as a key process for research intensive firms. Technovation, 36, 77–89. https://doi.org/10.1016/j.technovation.2014.10.003.
Article
Google Scholar
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., et al. (2010). How to improve R&D productivity: the pharmaceutical industry’s grand challenge. Nature Reviews Drug Discovery, 9(3), 203–214. https://doi.org/10.1038/nrd3078.
Article
Google Scholar
Pisano, G. P. (1994). Knowledge, integration, and the locus of learning: An empirical analysis of process development. Strategic Management Journal, 15(S1), 85–100. https://doi.org/10.1002/smj.4250150907.
Article
Google Scholar
Porter, M. E. (1980). Competitive strategy. New York: Free Press.
Google Scholar
Powell, W. W. (1998). Learning from Collaboration: Knowledge and Networks in the Biotechnology and Pharmaceutical Industries. California Management Review, 40(3), 228–240. https://doi.org/10.2307/41165952.
Article
Google Scholar
Powell, W. W., Koput, K. W., & Smith-Doerr, L. (1996). Interorganizational Collaboration and the Locus of Innovation: Networks of Learning in Biotechnology. Administrative Science Quarterly, 41(1), 116. https://doi.org/10.2307/2393988.
Article
Google Scholar
Powell, W. W., White, D. R., Koput, K. W., & Owen-Smith, J. (2005). Network dynamics and field evolution: The growth of interorganizational collaboration in the life sciences. American Journal of Sociology, 110(4), 1132–1205. https://doi.org/10.1086/421508.
Article
Google Scholar
Rafols, I., Hopkins, M. M., Hoekman, J., Siepel, J., O’Hare, A., Perianes-Rodríguez, A., et al. (2014). Big Pharma, little science? Technological Forecasting and Social Change, 81, 22–38. https://doi.org/10.1016/j.techfore.2012.06.007.
Article
Google Scholar
Ramos, J. (2003). Using TF-IDF to Determine Word Relevance in Document Queries. In: Proceedings of the first instructional conference on machine learning. 10.1.1.121.1424.
Rothaermel, F. T. (2001). Incumbent’s advantage through exploiting complementary assets via interfirm cooperation. Strategic Management Journal, 22(6–7), 687–699. https://doi.org/10.1002/smj.180.
Article
Google Scholar
Rothaermel, F. T., & Boeker, W. (2008). Old technology meets new technology: Complementarities, similarities, and alliance formation. Strategic Management Journal, 29(1), 47–77. https://doi.org/10.1002/smj.634.
Article
Google Scholar
Rothaermel, F. T., & Deeds, D. L. (2004). Exploration and exploitation alliances in biotechnology: A system of new product development. Strategic Management Journal, 25(3), 201–221. https://doi.org/10.1002/smj.376.
Article
Google Scholar
Rzakhanov, Z. (2008). Regulatory policy, value of knowledge assets and innovation strategy: The case of the orphan drug act. Research Policy, 37, 673–689. https://doi.org/10.1016/j.respol.2007.12.009.
Article
Google Scholar
Santos, F. M. (2003). The coevolution of firms and their knowledge environment: Insights from the pharmaceutical industry. Technological Forecasting and Social Change, 70(7), 687–715. https://doi.org/10.1016/S0040-1625(03)00031-3.
Article
Google Scholar
Saotome, C., Nakaya, Y., & Abe, S. (2016). Patent production is a prerequisite for successful exit of a biopharmaceutical company. Drug Discovery Today. https://doi.org/10.1016/j.drudis.2015.12.005.
Article
Google Scholar
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012). Diagnosing the decline in pharmaceutical R&D efficiency. Nature Reviews Drug Discovery, 11(3), 191–200. https://doi.org/10.1038/nrd3681.
Article
Google Scholar
Schuhmacher, A., Gassmann, O., & Hinder, M. (2016). Changing R&D models in research-based pharmaceutical companies. Journal of Translational Medicine. https://doi.org/10.1186/s12967-016-0838-4.
Article
Google Scholar
Stryker, J. B., Santoro, M. D., & Farris, G. F. (2012). Creating collaboration opportunity: Designing the physical workplace to promote high-tech team communication. IEEE Transactions on Engineering Management, 59(4), 609–620. https://doi.org/10.1109/TEM.2011.2170995.
Article
Google Scholar
Stuart, T. E., Ozdemir, S. Z., & Ding, W. W. (2007). Vertical alliance networks: The case of university–biotechnology–pharmaceutical alliance chains. Research Policy, 36(4), 477–498. https://doi.org/10.1016/j.respol.2007.02.016.
Article
Google Scholar
Tang, C. (2016). Accessed external knowledge, centrality of intra-team knowledge networks, and R&D employee creativity. R&D Management, 46(S3), 992–1005. https://doi.org/10.1111/radm.12160.
Article
Google Scholar
Thomke, S., & Kuemmerle, W. (2002). Asset accumulation, interdependence and technological change: Evidence from pharmaceutical drug discovery. Strategic Management Journal, 23(7), 619–635. https://doi.org/10.1002/smj.242.
Article
Google Scholar
Thongpapanl, N. (2012). The changing landscape of technology and innovation management: An updated ranking of journals in the field. Technovation. https://doi.org/10.1016/j.technovation.2012.01.001.
Article
Google Scholar
Tierney, R., Hermina, W., & Walsh, S. (2013). The pharmaceutical technology landscape: A new form of technology roadmapping. Technological Forecasting and Social Change, 80(2), 194–211. https://doi.org/10.1016/j.techfore.2012.05.002.
Article
Google Scholar
Trajtenberg, M. (1990). A penny for your quotes: Patent citations and the value of innovations. The RAND Journal of Economics. https://doi.org/10.2307/2555502.
Article
Google Scholar
Tralau-Stewart, C. J., Wyatt, C. A., Kleyn, D. E., & Ayad, A. (2009). Drug discovery: New models for industry–academic partnerships. Drug Discovery Today, 14(1–2), 95–101. https://doi.org/10.1016/j.drudis.2008.10.003.
Article
Google Scholar
Trott, P., & Hartmann, D. (2009). Why “open innovation” is old wine in new bottles. International Journal of Innovation Management, 13(04), 715–736. https://doi.org/10.1142/S1363919609002509.
Article
Google Scholar
Vakili, K., & McGahan, A. M. (2016). Health care’s grand challenge: Stimulating basic science on diseases that primarily afflict the poor. Academy of Management Journal., 59, 1917–1939. https://doi.org/10.5465/amj.2015.0641.
Article
Google Scholar
van de Vrande, V. (2013). Balancing your technology-sourcing portfolio: How sourcing mode diversity enhances innovative performance. Strategic Management Journal, 34(5), 610–621. https://doi.org/10.1002/smj.2031.
Article
Google Scholar
van Eck, N. J., & Waltman, L. (2010). Software survey: VOSviewer, a computer program for bibliometric mapping. Scientometrics, 84(2), 523–538.
Article
Google Scholar
van Merkerk, R. O., & Robinson, D. K. R. (2006). Characterizing the emergence of a technological field: Expectations, agendas and networks in Lab-on-a-chip technologies. Technology Analysis & Strategic Management, 18(3–4), 411–428. https://doi.org/10.1080/09537320600777184.
Article
Google Scholar
Vinet, L., & Zhedanov, A. (2011). A ‘missing’ family of classical orthogonal polynomials. Journal of Physics A: Mathematical and Theoretical, 44(8), 085201. https://doi.org/10.1088/1751-8113/44/8/085201.
MathSciNet
Article
MATH
Google Scholar
Waltman, L., van Eck, N. J., & Noyons, E. C. M. (2010). A unified approach to mapping and clustering of bibliometric networks. Journal of Informetrics. https://doi.org/10.1016/j.joi.2010.07.002.
Article
Google Scholar
Zucker, L. G., & Darby, M. R. (1997). Present at the biotechnological revolution: Transformation of technological identity for a large incumbent pharmaceutical firm. Research Policy, 26(4–5), 429–446.
Article
Google Scholar